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cancer patients. The aim of this study was evaluate the plasma con-
centrations of oxycodone and its demethylates and opioid-induced 
adverse effects based on cachexia stage in cancer patients receiving 
oxycodone.
Patients (or Materials) and Methods: Seventy patients receiving 
oxycodone for cancer pain at Hamamatsu University Hospital were 
enrolled. Cachexia was evaluated using the Glasgow Prognostic Score 
(GPS). Predose plasma concentrations of oxycodone, oxymorphone, 
and noroxycodone were determined at the titration dose. Opioid-
induced adverse effects were monitored for 2 weeks after the titra-
tion.
Results: Fourteen patients had a GPS of 0, 27 a GPS of 1, and 29 a 
GPS of 2. Plasma concentrations of oxycodone and oxymorphone 
but not noroxycodone in patients with a GPS of 2 were significantly 
higher than that with a GPS of 0. The metabolic ratios of noroxyco-
done but not oxymorphone to oxycodone in patients with a GPS of 1 
and 2 were significantly lower than in those with a GPS of 0. A higher 
GPS was associated with a higher incidence of somnolence, while 
the GPS did not affect the incidence of vomiting. Plasma concentra-
tions of oxycodone and oxymorphone were not associated with the 
incidence of adverse effects.
Conclusion: Cancer cachexia raised the plasma exposures of oxy-
codone and oxymorphone through the reduction of CYP3A but not 
CYP2D6. Although the cachexia elevated the incidence of somno-
lence, alterations in their pharmacokinetics were not associated with 
the incidence.
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Introduction: Many issues remain to be solved in regard to cannabi-
noid disposition, elimination time profiles and correlation between 
oral fluid (OF) and whole blood (WB) concentrations. Delta-9-
tetrahydrocannabinol (THC) in OF is usually indicative of a relatively 
recent cannabis exposure, but the study of other cannabinoids in OF 
and WB could also be helpful as a confirmatory test when applied 
for legal purposes.
Patients (or Materials) and Methods: A randomized, blinded, 2-way 
crossover study was conducted in 48 healthy volunteers (23 heavy 
and 25 occasional cannabis smokers) who received by smoking on 
each period, in random sequence, a cannabis joint (containing bed-
robinol, 11% THC, and traces of cannabidiol- CBD) or a placebo. 
WB was collected up to 2.5 hours after smoking. An additional WB 
sample at 3.5 hours, and OF samples were collected in heavy smok-
ers. Storage at –20°C and liquid-liquid extraction preceded analy-
sis by liquid chromatography-tandem mass spectrometry. THC, 
11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC 
(THCCOOH) were measured in WB. THC, THCCOOH, cannabi-
nol (CBN), CBD and delta-9-tetrahydrocannabinolic acid A (THC-A) 
were investigated in OF. WB pharmacokinetic parameters of THC 
and its metabolites were compared in heavy and occasional smokers. 
Correlations for these parameters between OF and WB were studied 
in heavy smokers.
Results: Before smoking, a significant difference (P < 0.001) was 
found in WB THCCOOH between heavy and occasional smokers: 
median THCCOOH was 20.1 µg/L (range, 2.50–93.9) and 0.14 µg/L 
(range, 0–16.6) respectively. No significant difference was found in 
WB for THC maximal concentrations (Cmax): median Cmax were 86.5 
µg/L (range, 37.1–192) and 75.1 µg/L (range, 8.20–168) respectively. 
Elimination half-lives (t1/2) in WB were also not significantly differ-
ent: median THC T1/2 were 0.97 hours (range, 0.55–1.87) and 0.84 
hour (range, 0.69–1.45) respectively; and median THCCOOH t1/2 
were 3.89 hours (range, 1.68–9.16) and 3.33 hours (range, 1.59–
17.3) respectively. Differences in the area under the curve (AUC) 
between both groups, were marginally significant for THC (P = 0.01) 
but highly significant (P < 0.001) for 11-OH-THC and THCCOOH. 
No correlation between WB and OF was found in heavy smokers for 
Cmax or AUC.
Conclusion: Our results suggest that the smoking regimen (heavy/
occasional) do not influence the elimination kinetic of cannabinoids 
in WB but do influence the initial THCCOOH level. No correlation 
was found between WB and OF for THC or THCCOOH parameters.
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Introduction: Methadone is known to be associated with pro-
longation of corrected QT time (QTc). Excretion of methadone 
is primarily renal in patients with normal renal function. It is 
unknown to what extent hemodialysis removes methadone. We 
investigated methadone kinetics and QTc during hemodialysis 
in methadone maintenance treatment (MMT) patients with end-
stage renal disease.
Patients (or Materials) and Methods: The Regional Ethics 
Committee approved the study. Data are given as median (range). 
Four patients with end-stage renal failure, 1 female and 3 males, 46 
(43–53) years, stabilized on methadone were included. Methadone 
was measured by UPLC-MMS in serum and hemodialysates col-
lected before morning methadone intake, every 30 minutes during 4 
hours hemodialysis and before afternoon dose, and in urine sampled 
at the end of hemodialysis. ECGs were recorded every 30 minutes 
during hemodialysis, and QT time was measured in lead v2 using 
tangential method and QTc was calculated with Bazzet’s formula. 
ECGs were read serially for each patient with blinding of number-
ing. Several routine biochemical tests were performed before and 
after hemodialysis.
Results: The daily methadone dose was 100 (60–120) mg. Serum-
methadone increased from Cmin of 1124 (547–1581) nmol/L to 
Cmax of 1806 (1237–2098) nmol/l after 85 (40–120) minutes. The 
apparent half-life of methadone was 12 (6.3–25) hours. A total of 
2.30 (1.25–3.70) % and 0.14 (0.03–0.26) % of daily methadone 
intake was collected, respectively, in hemodialysate and urine dur-
ing 4 hours. Renal clearance of methadone was 0.67 (0.31–1.20) 
mL/min, methadone clearance of hemodialysis was 17.10 (13.67–
20.61) mL/min and AUC of dose interval was 253.5 mg min/L. QTc 
increased from 395 (369–406) ms to 452 (407–479) ms with P = 
0.068,Wilcoxon paired comparison. The maximum QTc occurred 
